Key facts
- It has raised $720K across 1 recorded rounds; the latest was Seed Round ($515K) in Jul 2024.
- Vesicor Therapeutics has filed 2 Form Ds with the SEC since 2023, most recently May 2025 ($515K sold to 12 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·Watchlist + deal alerts for Vesicor Therapeutics
Funding rounds
1 roundsAbout Vesicor Therapeutics
Operator of a biopharmaceutical company intended for the treatment of various diseases. The company focuses on developing microvesicle-based therapeutics, enabling the biopharmaceutical market to explore novel treatments with the potential to address a broad range of medical conditions.
- Sector
- Healthcare
- HQ
- San Gabriel, CA, United States
- Website
- vesicor.com/
- Ownership
- Privately Held (backing)
Vesicor Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Vesicor Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Vesicor Therapeutics in its N-PORT filings yet. We sweep new filings monthly.